SVA:CC - Sernova to Participate in Multiple U.S. Healthcare Investor Conferences
(TheNewswire)
Sernova Engages Leading U.S.-Based HealthcareCommunications Firm to Broaden Awareness of Potential ‘FunctionalCure’ Technology for Type 1 Diabetes
LONDON, ONTARIO – TheNewswire - May 5, 2022 – Sernova Corp. (TSXV:SVA)(OTC:SEOVF) (FSE/XETRA:PSH), a clinical stage regenerative medicinecompany focused on developing a potential ‘functional cure’ fortype 1 diabetes (T1D) and other chronic diseases including hemophiliaA and thyroid disease, today announced that the company will beparticipating in several upcoming U.S. healthcare industry andinvestor conferences. Conference details are provided below.
The Company is also pleased to announce it has engagedNew York-based LifeSci Communications, a global life science andmedical technologies-focused communications and marketing agency.LifeSci Communications will assist Sernova to expand and elevate itsprofile through strategic communications and public relations. Sernovais also working with affiliate LifeSci Advisors LLC, a leadinginvestor relations consultancy firm serving life science companies,providing institutional investor communications and capital marketsoutreach services in support of the Company’s U.S. capital marketsobjectives.
“With multiple collaborations advancing across ourpipeline and growing interest in our best-in-class cell therapytherapeutic solution platform - consisting of immune protectedtherapeutic cells and our proprietary Cell Pouch ™ medical device - as a potential‘functional cure’ for multiple patient populations, the timing isright to drive awareness of our unique cell therapy proposition andunprecedented clinical results including the demonstration ofcontinuous insulin independence for over two years now in our mostadvanced Phase 1/2 T1D study patient, in contrast to the clinicalsetbacks of several of our peer companies,” commented Dr. PhilipToleikis, President & CEO of Sernova.
UPCOMING U.S. HEALTHCARE INDUSTRY ANDINSTITUTIONAL INVESTOR PRESENTATIONS
Event : Roth Capital’s Canada Corporate Access Day
Date : May 17, 2022
Format : Corporate presentation and 1x1 meetings with institutionalinvestors
Location : New York, NY
Event : H.C. Wainwright Global Life Sciences Conference
Date : May 24-25, 2022
Format : Corporate presentation and 1x1 meetings with institutionalinvestors
Location : Miami Beach, FL
Event : Truist Securities Cell Therapy Symposium
Date : June 28, 2022
Format : Panel expert and discussions
Location : New York, NY
ABOUT SERNOVA
Sernova is developing regenerative medicine celltherapeutic solutions using a medical device (Cell Pouch) and immuneprotected therapeutic cells / tissues (i.e. human donor cells,corrected human cells and stem cell-derived cells) to improve thetreatment and quality of life of people with chronic metabolicdiseases such as insulin-dependent diabetes, blood disorders includinghemophilia, and other diseases treated through cellular production ofproteins or hormones missing or in short supply within the body. Formore information, please visit www.sernova.com .
ABOUT SERNOVA’S CELL POUCH SYSTEMCELL THERAPY PLATFORM
The Cell Pouch, as part of the Cell Pouch System, is anovel, proprietary, scalable, implantable macro- encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. After implantation, the device incorporates withtissue, forming highly vascularized, native tissue chambers for thetransplantation and function of therapeutic cells, that releaseproteins and hormones as required to treat disease.
The Cell Pouch, along with therapeutic cells, has beenshown to provide long-term safety and efficacy in small and largeanimal models of diabetes and has been proven to provide abiologically compatible environment for insulin-producing cells inhumans in a Canadian first-in-human study. Sernova is currentlyconducting a Phase 1/2 clinical trial study at the University ofChicago. Encouraging interim results have been presented at severalinternational scientific conferences.
FOR FURTHER INFORMATION, PLEASECONTACT:
Investors and Analysts
Christopher Barnes Corey Davis, Ph.D.
VP, Investor Relations Managing Director
Sernova Corp. LifeSci Advisors, LLC
christopher.barnes@sernova.com cdavis@lifesciadvisors.com
Tel: 519-902-7923 Tel: 212-915-2577
Media
Elizabeth Miller, M.D.
LifeSci Communications
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extentthey are not recitations of historical facts, may constitute“forward-looking statements” that involve various risks,uncertainties, and assumptions, including, without limitation,statements regarding the prospects, plans, and objectives of thecompany. Wherever possible, but not always,words such as "expects", "plans","anticipates", "believes", "intends","estimates", "projects", "potential for"and similar expressions, or that events or conditions"will", "would", "may","could" or "should" occur are used to identifyforward-looking statements. These statements reflect management’sbeliefs with respect to future events and are based on informationcurrently available to management on the date such statements weremade. Many factors could cause Sernova’s actual results,performances or achievements to not be as anticipated, estimated orintended or to differ materially from those expressed or implied bythe forward-looking statements contained in this news release. Suchfactors could include, but are not limited to, the company’s abilityto secure additional financing and licensing arrangements onreasonable terms, or at all; ability to conduct all requiredpreclinical and clinical studies for the company’s Cell Pouch Systemand/or related technologies, including the timing and results of thosetrials; ability to obtain all necessary regulatory approvals, or on atimely basis; ability to in-license additional complementarytechnologies; ability to complete collaboration activities; ability tosecure collaboration arrangements from its collaboration activities;ability to execute its business strategy and successfully compete inthe market; and the inherent risks associated with the development ofbiotechnology combination products generally. Many of the factors arebeyond our control, including those caused by, related to, or impactedby the novel coronavirus pandemic. Investors should consult thecompany’s quarterly and annual filings available on www.sedar.com foradditional information on risks and uncertainties relating to theforward-looking statements. Sernova expressly disclaims any intentionor obligation to update or revise any forward-looking statements,whether as a result of new information, future events orotherwise.
Copyright (c) 2022 TheNewswire - All rights reserved.